Algo version: 0.98b
ETFMG Treatments Testing is listed at the AMEX Exchange
ETFMG Treatments Testing [GERM]
AMEX Sector: Financial Services Industry:Asset Management

Is ETFMG Treatments Testing stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, ETFMG Treatments Testing pays dividends. Last time was Friday 28th of June 2024 where the investors holding the stock on Thursday 27th of June 2024 were paid $0.087987 per share. Over the last 13 times between 2020 and 2024, ETFMG Treatments Testing has paid $0.911202 with an average of $0.07 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for ETFMG Treatments Testing 10 years ago, but if you had invested on Thursday 18th of June 2020 when the price was $25.15, you would have made a loss of $-5.99 per share or -23.82%

No, the average daily trading liquidity for ETFMG Treatments Testing is $1 202 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.

ETFMG Treatments Testing has no real debt, which is good in periods of high inflation. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.

We have calculated the inflation risk for ETFMG Treatments Testing to be medium [0.6 of 1]

US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.